These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 16906789)

  • 1. Memantine: a review of its use in Alzheimer's disease.
    Robinson DM; Keating GM
    Drugs; 2006; 66(11):1515-34. PubMed ID: 16906789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease].
    Gallarda T; Lôo H
    Encephale; 2004; 30(1):69-79. PubMed ID: 15029079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2005; 23(2):193-206. PubMed ID: 15748093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of memantine for the treatment of Alzheimer's disease.
    Ferris SH
    Expert Opin Pharmacother; 2003 Dec; 4(12):2305-13. PubMed ID: 14640929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias.
    Thomas SJ; Grossberg GT
    Clin Interv Aging; 2009; 4():367-77. PubMed ID: 19851512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of moderate to severe Alzheimer's disease: focus on memantine.
    Dominguez E; Chin TY; Chen CP; Wu TY
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):415-23. PubMed ID: 22212311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine for dementia.
    Areosa Sastre A; McShane R; Sherriff F
    Cochrane Database Syst Rev; 2004 Oct; (4):CD003154. PubMed ID: 15495043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine: a review of its use in moderate to severe Alzheimer's disease.
    McKeage K
    CNS Drugs; 2009 Oct; 23(10):881-97. PubMed ID: 19739697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of memantine for the treatment of dementia.
    Lo D; Grossberg GT
    Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine hydrochloride: pharmacological and clinical profile.
    Möbius HJ; Stöffler A; Graham SM
    Drugs Today (Barc); 2004 Aug; 40(8):685-95. PubMed ID: 15510240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on memantine in moderate to severe Alzheimer's disease.
    McKeage K
    Drugs Aging; 2010 Feb; 27(2):177-9. PubMed ID: 20104942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine.
    Jarvis B; Figgitt DP
    Drugs Aging; 2003; 20(6):465-76; discussion 477-8. PubMed ID: 12710865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
    Olivares D; Deshpande VK; Shi Y; Lahiri DK; Greig NH; Rogers JT; Huang X
    Curr Alzheimer Res; 2012 Jul; 9(6):746-58. PubMed ID: 21875407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU.
    Lyseng-Williamson KA; McKeage K
    Drugs Aging; 2013 Jan; 30(1):51-8. PubMed ID: 23229767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
    Bakchine S; Loft H
    J Alzheimers Dis; 2008 Feb; 13(1):97-107. PubMed ID: 18334761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
    Wilcock GK; Ballard CG; Cooper JA; Loft H
    J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.